Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates

Show simple item record

dc.contributor.author Boije af Gennäs, Gustav
dc.contributor.author Talman, Virpi
dc.contributor.author Yli-Kauhaluoma, Jari
dc.contributor.author Tuominen, Raimo K.
dc.contributor.author Ekokoski, Elina
dc.date.accessioned 2016-04-11T13:39:01Z
dc.date.available 2021-12-17T18:47:15Z
dc.date.issued 2011
dc.identifier.citation Boije af Gennäs , G , Talman , V , Yli-Kauhaluoma , J , Tuominen , R K & Ekokoski , E 2011 , ' Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates ' , Current Topics in Medicinal Chemistry , vol. 11 , no. 11 , pp. 1370-1392 .
dc.identifier.other PURE: 10787771
dc.identifier.other PURE UUID: 387c5f6a-87d4-4764-91d3-85b2ac900db7
dc.identifier.other WOS: 000291635100007
dc.identifier.other Scopus: 79956372197
dc.identifier.other ORCID: /0000-0002-0099-6085/work/39200645
dc.identifier.other ORCID: /0000-0002-2702-6505/work/39202590
dc.identifier.other ORCID: /0000-0003-0370-7653/work/39203380
dc.identifier.uri http://hdl.handle.net/10138/161200
dc.description.abstract The second messenger diacylglycerol (DAG) plays a central role in the signal transduction of G-protein coupled receptors and receptor tyrosine kinases by binding to C1 domain of effector proteins. C1 domain was first identified in protein kinase C (PKC) which comprises a family of ten isoforms that play roles in diverse cellular processes such as proliferation, apoptosis and differentiation. Aberrant signaling through PKC isoforms and other C1 domain-containing proteins has been implicated in several pathological disorders. Drug discovery concerning C1 domains has exploited both natural products and rationally designed compounds. Currently, molecules from several classes of C1 domain-binding compounds are in clinical trials; however, still more have the potential to enter the drug development pipeline. This review gives a summary of the recent developments in C1 domain-binding compounds. en
dc.format.extent 23
dc.language.iso eng
dc.relation.ispartof Current Topics in Medicinal Chemistry
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Protein kinase C
dc.subject C1 domain
dc.subject drug discovery
dc.subject cancer
dc.subject Alzheimer's disease
dc.subject bryostatins
dc.subject ingenol-3-angelate
dc.subject DAG-lactones
dc.subject PROTEIN-KINASE-C
dc.subject CONFORMATIONALLY CONSTRAINED ANALOGS
dc.subject CHRONIC LYMPHOCYTIC-LEUKEMIA
dc.subject ACTIVATOR-BINDING DOMAIN
dc.subject PHORBOL ESTER RECEPTOR
dc.subject CELLS IN-VITRO
dc.subject NF-KAPPA-B
dc.subject NEURONAL ELAV PROTEINS
dc.subject LACTONES DAG-LACTONES
dc.subject PROSTATE-CANCER CELLS
dc.subject 317 Pharmacy
dc.title Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates en
dc.type Review Article
dc.contributor.organization Faculty of Pharmacy
dc.contributor.organization Division of Pharmaceutical Chemistry and Technology
dc.contributor.organization Division of Pharmacology and Pharmacotherapy
dc.description.reviewstatus Peer reviewed
dc.relation.issn 1568-0266
dc.rights.accesslevel openAccess
dc.type.version acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Boije_et_al_2011_CurrTopMedChem_POSTPRINT.pdf 1.359Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record